Clinical Efficacy Of Unani Formulations Araq Mundi (Sphaeranthus Indicus) And Raughan Kamela (Mallotus Philipensis) In NarFarsi (Eczema): A Randomized Open Labelled Comparative Clinical Trial
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- Reduction in EASI Score from baseline
研究概览
简要总结
NarFarsi(Eczema) is an inflammatory condition of skin .The disease manifests as Pruritus, erythema ,edema ,vesicles, scaling and lichenification[1]Eczema is classified into two broad groups .1)Exogenous: where external stimuli trigger development of eczema e.g Irritant dermatitis. 2) Endogenous:where constitutional factors predispose the patient to developing an eczema e.g Atopic dermatitis .According to Unani system of medicine it may be caused by su i mizaj sada and su i mizaj maddi due to abnormal Akhlat involvement , the cause include safra(yelow bile) mixed with sawda(black bile)or Hadd safra (acrid yellow bile )mixed with Dam (sanguine). The treatment modulation of NarFarsi includes ingredients with anti inflammatory ,blood purifying (musaffi e dam) immunomodulatory and skin soothing effects. This integrative approach addresses symptoms and immune balance while aiming to restore skin barrier function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)(—)
- 性别
- All
入选标准
- •1.Age 18 years to 60years 2.Both gender 3.Diagnosis made on the basis of Hannifin and Rajka criteria 4.Eczema of mild to moderate in severity 5.Participants who have agreed to sign the informed consent form.
排除标准
- •1.Participants below 18 and above 60 years of age 2.Participants with Autoimmune and other skin diseases 3.Eczema due to secondary infection 4.Pregnant and lactating women 5.Participant not willing to attend treatment schedule regularly.
结局指标
主要结局
Reduction in EASI Score from baseline
时间窗: Baseline | 2nd week | 4th week | 6th week
次要结局
- Improvement in DLQI Score from baseline(Improvement in SCORAD from baseline)
研究者
Dr Farzana Anjum A
Government Unani Medical College Chennai
